A Mendelian randomization study of serum uric acid with the risk of venous thromboembolism

Arthritis Res Ther. 2023 Jul 19;25(1):122. doi: 10.1186/s13075-023-03115-6.

Abstract

Background: Observational studies have linked hyperuricemia with venous thromboembolism (VTE). We aimed to investigate whether there are causal relationships between uric acid levels and VTE and its subtypes, including deep venous thrombosis (DVT) of the lower extremities and pulmonary embolism (PE).

Methods: We utilized Mendelian randomization (MR) analysis to estimate the causal association in European individuals. We extracted two sets of polygenic instruments strongly associated (p < 5 × 10-8) with uric acid from the CKDGen consortium and UK biobank, respectively. Genetic associations with the risk of VTE, DVT, and PE were obtained from the FinnGen biobank. We used the inverse-variance weighted method as the preliminary estimate. Additionally, we employed MR-Egger, weighted median, and Mendelian randomization pleiotropy residual sum and outlier method as complementary assessments. Sensitivity analyses were performed to test for pleiotropic bias.

Results: The genetically instrumented serum uric acid levels had no causal effects on VTE, DVT, and PE. Two sets of polygenic instruments used for exposure, along with three complementary MR methods, also yielded no significant association.

Conclusions: Our MR analysis provided no compelling evidence for a causal relationship of serum uric acid with the risk of VTE. This suggests that uric acid-lowering therapies in patients with hyperuricemia may not be effective in reducing the likelihood of developing VTE.

Keywords: Mendelian randomization; Uric acid; Venous thromboembolism.

MeSH terms

  • Genome-Wide Association Study
  • Humans
  • Hyperuricemia* / genetics
  • Lower Extremity
  • Mendelian Randomization Analysis
  • Uric Acid
  • Venous Thromboembolism* / genetics

Substances

  • Uric Acid